Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi / Rigolin, G.M., Soddu, S., Dondolin, R., Frustaci, A.M., Scortechini, I., Mauro, F.R., Angotzi, F., Motta, M., Scarfo, L., Mengarelli, A., Giordano, A., Martinelli, S., Patti, C., Sportoletti, P., Sanna, A., Maschio, N., Riccioni, R., Vigano, C.V., Tafuri, A., Piciocchi, A., et al.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 208:5(2026), pp. 1816-1820. [10.1111/bjh.70401]
Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi
Scarfo L.;Maschio N.;Ferreri A. J. M.;Ghia P.Penultimo
;
2026-01-01
| File | Dimensione | Formato | |
|---|---|---|---|
|
Br J Haematol - 2026 - Rigolin - Incidence of severe COVID‐19 in patients with chronic lymphocytic leukaemia or indolent.pdf
accesso aperto
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Creative commons
Dimensione
446.02 kB
Formato
Adobe PDF
|
446.02 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
